Antibiotic use as a risk factor for irritable bowel syndrome: Results from a nationwide, case-control study

被引:5
作者
Staller, Kyle [1 ,2 ,3 ]
Olen, Ola [4 ]
Soderling, Jonas [4 ,5 ]
Roelstraete, Bjorn [5 ]
Tornblom, Hans [6 ]
Kuo, Braden [1 ,2 ]
Nguyen, Long H. [1 ,2 ,3 ]
Ludvigsson, Jonas F. [5 ,7 ,8 ]
机构
[1] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA
[2] Harvard Med Sch, Boston, MA USA
[3] Massachusetts Gen Hosp, Clin & Translat Epidemiol Unit, Boston, MA USA
[4] Karolinska Inst, Clin Epidemiol Div, Stockholm, Sweden
[5] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden
[6] Univ Gothenberg, Inst Med, Gothenburg, Sweden
[7] Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY USA
[8] Orebro Univ Hosp, Dept Paediat, Orebro, Sweden
关键词
MICROBIOTA; EPIDEMIOLOGY; EXCRETION; REGISTER; DIARRHEA; THERAPY;
D O I
10.1111/apt.17736
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: The microbiome plays an important role in the pathophysiology of irritable bowel syndrome (IBS). Antibiotic use can fundamentally alter gut microbial ecology. We examined the association of antibiotic use with IBS in a large population-based investigation.Methods: A case-control study with prospectively collected data on 29,111 adult patients diagnosed with IBS in Sweden between 2007 and 2016 matched with 135,172 controls. Using a comprehensive histopathology cohort, the Swedish Patient Register, and the Prescribed Drug Register, we identified all consecutive cases of IBS in addition to cumulative antibiotic dispensations accrued until 1 year prior to IBS (exclusionary period) for cases and time of matching for up to five general population controls matched on the basis of age, sex, country and calendar year. Conditional logistic regression estimated multivariable-adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for the risk of IBS.Results: Patients with IBS (n = 29,111) were more likely than controls (n = 135,172) to have used antibiotics up to 1 year prior to diagnosis (74.9% vs. 57.8%). After multivariable adjustment, this translated to a more than twofold increased odds of IBS (OR 2.21, 95% CI 2.14-2.28) that did not differ according to age, sex, year of IBS diagnosis or IBS subtype. Compared to none, 1-2 (OR 1.67, 95% CI 1.61-1.73) and >= 3 antibiotics dispensations (OR 3.36, 95% CI 3.24-3.49) were associated with increased odds of IBS (p for trend <0.001) regardless of the antibiotic class.Conclusions: Prior antibiotics use was associated with an increased odds of IBS with the highest risk among people with multiple antibiotics dispensations.
引用
收藏
页码:1175 / 1184
页数:10
相关论文
共 32 条
  • [21] Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation.
    Pimentel, Mark
    Lembo, Anthony
    Chey, William D.
    Zakko, Salam
    Ringel, Yehuda
    Yu, Jing
    Mareya, Shadreck M.
    Shaw, Audrey L.
    Bortey, Enoch
    Forbes, William P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (01) : 22 - 32
  • [22] Shane AL, 2017, CLIN INFECT DIS, V65, P1963, DOI [10.1093/cid/cix959, 10.1093/cid/cix669]
  • [23] Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study
    Sperber, Ami D.
    Bangdiwala, Shrikant, I
    Drossman, Douglas A.
    Ghoshal, Uday C.
    Simren, Magnus
    Tack, Jan
    Whitehead, William E.
    Dumitrascu, Dan L.
    Fang, Xuicai
    Fukudo, Shin
    Kellow, John
    Okeke, Edith
    Quigley, Eamonn M. M.
    Schmulson, Max
    Whorwell, Peter
    Archampong, Timothy
    Adibi, Payman
    Andresen, Viola
    Benninga, Marc A.
    Bonaz, Bruno
    Bor, Serhat
    Fernandez, Luis Bustos
    Choi, Suck Chei
    Corazziari, Enrico S.
    Francisconi, Carlos
    Hani, Albis
    Lazebnik, Leonid
    Lee, Yeong Yeh
    Mulak, Agata
    Rahman, M. Masudur
    Santos, Javier
    Setshedi, Mashiko
    Syam, Ari Fahrial
    Vanner, Stephen
    Wong, Reuben K.
    Lopez-Colombo, Aurelio
    Costa, Valeria
    Dickman, Ram
    Kanazawa, Motoyori
    Keshteli, Ammar Hassanzadeh
    Khatun, Rutaba
    Maleki, Iradj
    Poitras, Pierre
    Pratap, Nitesh
    Stefanyuk, Oksana
    Thomson, Sandie
    Zeevenhooven, Judith
    Palsson, Olafur S.
    [J]. GASTROENTEROLOGY, 2021, 160 (01) : 99 - +
  • [24] Postinfectious Irritable Bowel Syndrome
    Spiller, Robin
    Garsed, Klara
    [J]. GASTROENTEROLOGY, 2009, 136 (06) : 1979 - 1988
  • [25] Is traveler's diarrhea a significant risk factor for the development of irritable bowel syndrome? A prospective study
    Stermer, Edy
    Lubezky, Anat
    Potasman, Israel
    Paster, Eran
    Lavy, Alexandra
    [J]. CLINICAL INFECTIOUS DISEASES, 2006, 43 (07) : 898 - 901
  • [26] Identification of irritable bowel syndrome in the Swedish National Patient Register: a validation study
    Tornkvist, Navkiran T.
    Backman, Ann-Sofie
    Linder, Marie
    Altman, Maria
    Simren, Magnus
    Olen, Ola
    Tornblom, Hans
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2023, 58 (07) : 709 - 717
  • [27] Prevalence and impact of disorders of Gut-Brain interaction in Sweden
    Tornkvist, Navkiran Thind
    Simren, Magnus
    Hreinsson, Johann P.
    Tack, Jan
    Bangdiwala, Shrikant I.
    Sperber, Ami D.
    Palsson, Olafur S.
    Josefsson, Axel
    Tornblom, Hans
    [J]. NEUROGASTROENTEROLOGY AND MOTILITY, 2023, 35 (06)
  • [28] Villarreal Armando A, 2012, WMJ, V111, P17
  • [29] The First Decade with the Swedish Prescribed Drug Register - A Systematic Review of the Output in the Scientific Literature
    Wallerstedt, Susanna M.
    Wettermark, Bjorn
    Hoffmann, Mikael
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2016, 119 (05) : 464 - 469
  • [30] The new Swedish Prescribed Drug Register -: Opportunities for pharmacoepidemiological research and experience from the first six months
    Wettermark, Bjorn
    Harnmar, Niklas
    MichaelFored, C.
    Leimanis, Andrejs
    Olausson, Petra Otterblad
    Bergman, Ulf
    Persson, Ingemar
    Sundstrom, Anders
    Westerholm, Barbro
    Rosen, Mans
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 (07) : 726 - 735